Drug Database
ME

meningococcal polysaccharide vaccine (group A/C/Y/W135)

✓ Approved

Walvax Biotechnology · Vaccine · Vaccine

What is meningococcal polysaccharide vaccine (group A/C/Y/W135)?

meningococcal polysaccharide vaccine (group A/C/Y/W135) is a vaccine developed by Walvax Biotechnology. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection or subcutaneous injection.

Drug Profile

CompanyWalvax Biotechnology
Drug ClassVaccine
RouteInjectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Walvax Biotechnology

Therapeutic Indications

meningococcal polysaccharide vaccine (group A/C/Y/W135) is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsMeningococcal bacteraemia✓ Approved

Related Research Articles

PubMedInternational journal of legal medicine2026-09-19

Genetic origin and forensic analysis of han populations from four districts in Shanghai, China, based on Y-chromosome STR and SNP markers.

Sun Haolin H, Liu Yanan Y, Liu Tiezhu T, Tang Zhen Z et al.

Y-short tandem repeats (STRs) and Y-single nucleotide polymorphisms (SNPs) on the Y chromosome are genetic markers unique to men. They are widely used in identification, forensic medicine and paternal lineage tracing. Because of their strict paternal genetic characteristics, they have become a powerful means to trace the evolution of paternal lineages and populations. In this study, 38 Y-STR loci and 250 Y-SNP loci were genotyped, and a dataset was constructed for Qingpu Han (n = 396), Songjiang Han (n = 386), Jinshan Han (n = 384), and Fengxian Han (n = 372) populations in Shanghai. The Yfiler platinum genotyping system yielded the highest haplotype diversity (HD): Qingpu (0.99995), Songjiang (0.99996), Jinshan (0.99988) and Fengxian (0.99993); additionally, unique haplotypes accounted for 97.31%, 96.09%, 97.98%, and 98.45%, respectively. Y-STR variants, including null alleles, intermediate alleles and multi-allelic patterns, were also included. Moreover, Permutational Multivariate Analysis of Variance (PERMANOVA) and Principal Co-ordinates Analysis (PCoA)/classical multidimensional scale analysis (classical MDS) maps based on 17 Y-STRs revealed the unique genetic structure of each population. A joint analysis of Y-SNPs and Y-STRs clarified the evolutionary path of populations in the four districts. The results of haplotype network analysis showed that the Zhejiang Han population had more paternal genetic contributions to the formation of the Han populations in Shanghai's Qingpu, Songjiang, Jinshan, and Fengxian districts. In this study, through a joint analysis of Y-STRs and Y-SNPs, the paternal genetic structure of Han populations in four districts of Shanghai were explored in depth. The paternal origin of O1a in four districts of Shanghai may stem from population dispersal from the Zhejiang region. Applying Y-SNP haplogroups to forensic analyses can provide clues for familial investigations.

PMID 42760425
Read full article →
PubMedBMC psychiatry2026-09-19

Event-related potential correlates of ESS-C-defined relapse-risk status in clinically stable patients with schizophrenia: a cross-sectional study.

Feng Yang Y, Dong Junhui J, Lu Minle M, Zhang Na N et al.

Schizophrenia (SCZ) is associated with a high relapse rate, but objective electrophysiological correlates of relapse-related clinical vulnerability remain insufficiently understood. Event-related potential (ERP) components, such as P3 and N2, have been widely investigated as markers of cognitive dysfunction in SCZ. However, relatively few studies have examined ERP characteristics in clinically stable patients stratified according to early warning signs of relapse. The present study investigated ERP characteristics in clinically stable patients with SCZ classified according to the Early Signs Scale-Chinese version (ESS-C), aiming to explore whether ERP components are associated with ESS-C-defined relapse-risk status. A cross-sectional study design was adopted. A total of 70 patients with SCZ and 35 healthy controls (HCs) were initially recruited. After electroencephalography (EEG) preprocessing, 90 participants were included in the final analysis, comprising 30 HCs, 30 patients in the non-relapse-risk group (NR), and 30 patients in the relapse-risk group (RR). Patients with SCZ were classified into the NR and RR groups according to the ESS-C cutoff. ERP data were recorded using a three-stimulus visual oddball paradigm. The amplitudes and latencies of N2 at Cz and P3 at CPz were extracted, and their associations with negative symptoms were analyzed. A significant overall group effect was observed for P3 amplitude (F = 9.914, P < 0.001), with Bonferroni-corrected post hoc comparisons showing significantly higher P3 amplitude in the RR group than in the HC group (P < 0.001), while the NR group showed intermediate values. Sensitivity analysis restricted to patients with SCZ showed that ESS-C-defined relapse-risk status was significantly associated with P3 amplitude after adjustment for available clinical variables. N2 amplitude was positively correlated with negative symptom severity (r = 0.278, P < 0.05). Clinically stable patients with SCZ still exhibit abnormal neural information processing. P3 amplitude may be associated with ESS-C-defined relapse-risk status in clinically stable SCZ, whereas N2 may be related to negative symptom severity. These findings provide preliminary evidence that ERP components may be associated with relapse-risk status in clinically stable SCZ. NA.

PMID 42760537
Read full article →
PubMedAAPS PharmSciTech2026-09-19

Comprehensive Stability Assessment of Squalene in a Nanoemulsion Adjuvant and the SpiN-Tec Vaccine: HPLC Quantification, Stress Testing, and Stability Studies.

Gomes Isabela Pereira IP, Rivelli Graziella Gomes GG, Bagno Flávia Fonseca FF, Hojo-Souza Natália Satchiko NS et al.

Squalene-based nanoemulsions are widely used as adjuvants in vaccine formulations, but their stability can be affected by environmental factors such as pH, oxidative stress, temperature, and light. We have produced a squalene nanoemulsion (CTVad1) to support the clinical development of new vaccines. This study aimed to develop and validate an HPLC method for squalene quantification in SpiN-Tec, a recombinant protein vaccine against COVID-19. We also aimed to evaluate the stability of the CTVad1 adjuvant and SpiN-Tec under controlled storage conditions. A reversed-phase HPLC method was developed and validated, and comprehensive forced degradation studies were performed on the raw material and SpiN-Tec under acidic, basic, oxidative, thermal, and photolytic conditions to demonstrate the stability-indicating capability of the method. Physicochemical, morphological, and biological characteristics were assessed, and stability studies of both the vaccine and the CTVad1 adjuvant were performed under accelerated and long-term conditions. The HPLC method was selective, precise, accurate, linear, and robust. Squalene raw material degraded under all tested conditions, whereas formulation in nano-sized globules improved its stability, with degradation observed only under hydrogen peroxide and light exposure. CTVad1 remained stable over time, exhibiting only minor, non-critical changes within the specification limits in both accelerated and long-term stability studies, regardless of the glass packaging used (clear or amber). In addition, the SpiN-Tec vaccine maintained its physicochemical and biological integrity under all tested conditions, with all evaluated parameters remaining within the established specification ranges. Our findings demonstrate that proper formulation, packaging, and storage conditions can preserve squalene stability in nanoemulsion-based vaccines, ensuring the quality, safety, and efficacy of the SpiN-Tec vaccine and its adjuvant throughout shelf life.

PMID 42760453
Read full article →
PubMedOcular immunology and inflammation2026-09-19

Bilateral Maculopathy in an Infant Following Measles, Mumps, Rubella, and Varicella-Zoster (MMRV) Vaccination.

Ben-Avi Ravid R, Amer Radgonde R

To report on the long-term clinical outcome of a healthy infant who presented with posterior uveitis following the administration of the combined measles, mumps, rubella, and varicella (MMRV) vaccine. Descriptive case report. A 13-month-old infant presented with bilateral visual loss two weeks after receiving the MMRV vaccine. Ophthalmic examination revealed bilateral retinitis and retinal vasculitis with exudative retinal detachment. Extensive infectious work-up was conducted including serologic exams and PCR testing of blood, aqueous humor, cerebrospinal fluid and urine. Serological tests for measles yielded positive IgM and IgG titers. PCR testing for measles in the aqueous humor and urine was negative. Neurologic assessment and neuroimaging were unremarkable, excluding central nervous system involvement. Empiric systemic antiviral and corticosteroid therapy was initiated. Gradual resolution of posterior uveitis ensued, culminating in bilateral macular scars. Over a six-year follow-up period, the patient demonstrated stable ocular findings with no evidence of recurrent inflammation or systemic autoimmune disease. Final visual acuity was 6/9 in each eye. This case represents a rare occurrence of non-necrotizing retinitis following MMRV vaccination. To our knowledge, this is the first report describing the sequential OCT characteristics of presumed measles vaccine-associated retinitis. The prolonged follow-up period supports the absence of an alternative etiology and provides valuable insight into the long-term course and visual prognosis of vaccine-associated retinopathy.

PMID 42760840
Read full article →
PubMedEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026-09-19

Efficacy and durability of palatal surgery in the treatment of simple snoring: a long-term follow-up study.

De Santis Sante S, Galassi Stefania S, Cambi Jacopo J

To evaluate the long-term efficacy and durability of barbed anterior pharyngoplasty (BAP) in patients with simple snoring (AHI < 5) and to assess the prognostic value of palatal vibration patterns observed during drug-induced sleep endoscopy (DISE). In a prospective cohort study, 37 adult patients with habitual snoring, AHI < 5 on baseline polysomnography, and isolated palatal vibration at DISE were enrolled between 2018 and 2024. Patients were classified according to palatal vibration pattern as concentric (C) or anteroposterior (AP). All subjects underwent standardized BAP. Outcomes at 36 months included Snoring Index (SI), bed partner-reported Visual Analog Scale (VAS) for snoring severity, Epworth Sleepiness Scale (ESS), snoring tolerability, progression to mild OSA (AHI 5-15), adjunctive therapies, and complications. Thirty-seven patients (24 M, 13 F; mean age 44.7 ± 10.2 years) completed 36-month follow-up. Overall, 51.4% achieved ≥ 50% reduction in SI, and 64.9% had improved VAS scores. Improvements were significantly greater in the AP group compared with the C group (SI reduction ≥ 50%: 70.6% vs. 36.8%, p = 0.012; VAS improvement: 76.5% vs. 55%, p = 0.03). Snoring was considered tolerable by bed partners in 51.3% overall (70.6% AP vs. 35.0% C; p = 0.018). Four patients (10.8%) progressed to mild OSA, predominantly in the C group (3/4; p = 0.048). No major complications were observed. In patients with simple snoring (AHI < 5), BAP provides durable reduction of palatal vibration and snoring symptoms at three years, particularly in those exhibiting anteroposterior vibration on DISE. DISE-based vibration pattern recognition may improve patient selection; concentric vibration patterns may benefit from alternative or combined approaches.

PMID 42760364
Read full article →
PubMedMedicine2026-09-19

The safety and efficacy of different anti-tuberculosis regimens containing Lzd for RR/MDR/Pre-XDR-TB patients in China.

Tang Xian-Zhen XZ, Ma Yao Y, Tang Shen-Jie SJ, Chen Qing Q et al.

China remains a high-burden country for rifampicin-resistant tuberculosis. The treatment of drug-resistant tuberculosis is expensive, with many adverse drug reactions and greater difficulty to cure. Searching for appropriate treatment regimens is urgent. A retrospective study was conducted on HIV-negative patients aged 18 to 60 years with rifampicin- or multidrug- or pre-extensively drug-resistant tuberculosis (RR/MDR/Pre-XDR-TB) at the Public Health Clinical Center of Chengdu, China from May 1, 2018 to July 31, 2022. Patients were divided into 3 groups: linezolid (Lzd) + bedaquiline (Bdq) containing group (regimen A), Lzd + delamanid (Dlm) containing group (regimen B), and Lzd + other drugs containing group (regimen C, not containing Bdq or Dlm). A total of 142 RR/MDR/Pre-XDR-TB patients were included (63 in regimen A, 34 in regimen B, and 45 in regimen C). At 2 months of treatment, 1 patient was lost to follow-up in regimen A and regimen C, respectively. At 6 months of treatment, 3 patients were lost to follow-up in regimen A and regimen C, respectively, and 2 patients were lost to follow-up in regimen B. The sputum culture conversion rates of RR/MDR/Pre-XDR-TB patients in regimen A, B, and C at the end of 2 and 6 months were (72.6% [45/62] vs 64.7% [22/34] vs 18.2% [8/44]) and (95.0% [57/60] vs 90.6% [29/32] vs 81.0% [34/42]), respectively (P < .05). 88.2% (30/34) of the Dlm group used Lzd-Dlm-clofazimine (Cfz)-cycloserine (Cs) containing regimens. 7.9% (5/63) of patients stopped using Bdq due to corrected QT interval by Fredericia >500 ms. 2.9% (1/34) of patients with corrected QT interval by Fredericia prolongation and an increase of 88 ms from baseline stopped Dlm. No patient experienced any malignant heart disease events. Due to related adverse events of Lzd, 14.1% (20/142) reduced Lzd dosage and 6.3% (9/142) had permanent discontinuation of Lzd. 6-month Lzd + (Bdq or Dlm) containing regimens were associated with favorable early culture conversion and showed good safety among HIV-negative patients aged 18 to 60 years with RR/MDR/Pre-XDR-TB. Lzd-Dlm-Cfz-Cs containing regimens may serve as promising candidate regimens for future research on rifampicin-resistant tuberculosis. Multicenter prospective studies with longer follow-up and definitive treatment outcomes are needed to establish comparative effectiveness or treatment superiority of these regimens.

PMID 42760708
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about meningococcal polysaccharide vaccine (group A/C/Y/W135)